Does moxonidine reduce Achilles tendon or musculoskeletal pain in women with polycystic ovarian syndrome? A secondary analysis of a randomised controlled trial

Table 3 UTC data

Data	Group	Pre-intervention	Post-intervention	2-way ANOVA p-value
Echotype I + II %	Placebo	93.5 ± 5.6	96.0 ± 3.5	Group = 0.45 Time-point = 0.10 Group x Time-point = 0.64
Echotype I + II %	Moxonidine	94.9 ± 4.0	96.3 ± 3.2	Group = 0.45 Time-point = 0.10 Group x Time-point = 0.64
Mean normal CSA	Placebo	57.8 ± 12.6	59.6 ± 9.6	Group = 0.02* Time-point = 0.53 Group x Time-point = 0.92
Mean normal CSA	Moxonidine	65.9 ± 14.5	68.4 ± 14.3	Group = 0.02* Time-point = 0.53 Group x Time-point = 0.92
Mean total CSA	Placebo	61.9 ± 14.3	62.0 ± 9.9	Group = 0.03* Time-point = 0.81 Group x Time-point = 0.83
Mean total CSA	Moxonidine	69.3 ± 15.0	71.0 ± 14.7	Group = 0.03* Time-point = 0.81 Group x Time-point = 0.83
AP diameter (mm)	Placebo	6.2 ± 1.1	6.1 ± 0.8	Group = 0.59 Time-point = 0.92 Group x Time-point = 0.51
AP diameter (mm)	Moxonidine	6.2 ± 1.1	6.3 ± 1.2	Group = 0.59 Time-point = 0.92 Group x Time-point = 0.51

ISSN: 1472-6823